Status:
UNKNOWN
Efficacy and Safety of Zolmitriptan by Sublingual Administration
Lead Sponsor:
Xijing Hospital
Conditions:
Cluster Headache
Eligibility:
All Genders
18-70 years
Phase:
PHASE4
Brief Summary
The purpose is to evaluate the effectiveness and safety profile of zolmitriptan by Sublingual administration for the acute treatment of Cluster headache.
Detailed Description
Cluster headache is a primary neurological disorder characterized by intensive attacks and severe sharp headache, can cause a range of symptoms such as conjunctival congestion, runny nose, miosis, for...
Eligibility Criteria
Inclusion
- Patients older than or equal to 18 years and less than 70 years;
- The diagnosis of cluster headache is made according to The International Classification of Headache Disorders: 3rd edition (beta version)(ICHD-III β);
- Consent form signed by the participant or his/her authorized surrogate.
Exclusion
- Patients had primary or secondary headache disorders other than cluster headache;
- Female subjects of childbearing age will be excluded if they were pregnant, lactating or planning a pregnancy in the next year or if they were not using an adequate form of birth control;
- Patients will be excluded if they had significant medical or psychiatric disease;
- Patients will be excluded if they had coronary heart disease or not suitable for the treatment of zolmitriptan.
Key Trial Info
Start Date :
January 1 2018
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
April 30 2019
Estimated Enrollment :
71 Patients enrolled
Trial Details
Trial ID
NCT03377257
Start Date
January 1 2018
End Date
April 30 2019
Last Update
December 19 2017
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.